Calfactant

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 9, 2001, Pages 1479-1493

  Willson, D ^a  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

ALEC ; Alveofact ; Calf lung lavage; Calf lung surfactant extract; Calfactant; Curosurf ; Exosurf ; Infasurf ; SP A; SP B; SP C; SP D; Surfactant; Surfactant associated proteins; Surfixen ; Survanta ; Venticute

Indexed keywords

ARTIFICIAL LUNG SURFACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LIPID; LUCINACTANT; LUNG SURFACTANT EXTRACT; LUSUPULTIDE; PROTEIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DRUG CONTAMINATION; DRUG DEVELOPMENT; DRUG EFFICACY; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LAMB; LUNG INJURY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NONHUMAN; RAT; SURFACE TENSION; SWINE;

ANIMALS; BIOLOGICAL PRODUCTS; HUMANS; PULMONARY SURFACTANTS; SURFACE-ACTIVE AGENTS;

EID: 0034850668     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.9.1479     Document Type: Article

References (66)

1. Surfactant for the treatment of respiratory distress syndrome
2. Role of pulmonary surfactant in the development and treatment of adult respiratory distress syndrome
3. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome
4. Surfactant content in children with inflammatory lung disease
5. Surfactant abnormalities in patients with respiratory failure after multiple trauma
6. The surfactant system and lung phospholipid biochemistry
7. Surfactant: Composition, structure, and metabolism
8. Macromolecular organization of natural and recombinant lung surfactant protein SP-28-36: Structural homology with the complement factor C1q
9. Molecular structure of pulmonary surfactant protein D (SP-D)
10. Pulmonary surfactant proteins
11. Pulmonary SP-A enhances adsorption and appears to induce surface sorting of lipid extract surfactant
12. Surfactant protein A and surfactant protein D in health and disease
13. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis causing respiratory failure in newborn mice
14. Altered surfactant function and structure in SP-A gene targeted mice
15. Generation of an SP-C deficient mouse by targeted gene inactivation
16. Congenital pulmonary alveolar proteinosis: Failure of treatment with extracorporeal life support
17. Brief report: Deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis
18. Number and cell characteristics of the normal human lung
19. Commercial versus Native Surfactants. Surface activity, molecular components, and the effect of calcium
20. Surfactant inhibition by plasma proteins: Differential sensitivity of various surfactant preparation
21. Natural vs. synthetic surfactants in neonatal respiratory distress syndrome
22. Data on file
23. Early versus late surfactant treatment in preterm infants of 27 to 32 weeks' gestational age: A multicenter controlled clinical trial
24. Porcine-derived lung surfactant. A review of the therapeutic efficacy and clinical tolerability of a natural surfactant preparation (Curosurf) in neonatal respiratory distress syndrome
25. Colfosceril palmitate: A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome
26. Dry artificial surfactant and its effect on very premature babies
27. Comparison of rSP-C surfactant with natural and synthetic surfactants after late treatment in a rat model of the acute respiratory distress syndrome
28. Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury
29. Bronchopulmonary segmental lavage with surfaxin (KL4-surfactant) for acute respiratory distress syndrome
30. Enhancement of biophysical activity of lung surfactant extracts and phospholipid-apoprotein mixtures by surfactant protein A
31. Surface chemistry of L-α-dimpalmitoyl lecithin at the air-water interface
32. Surface active materials from dog lung. II. Composition and physiologic correlations
33. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants
34. Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant deficient rats
35. Structures of surfactant films: A scanning force microscopy study
36. Comparison of four surfactants: In vitro surface properties and responses of preterm lambs to treatment at birth
37. Natural and artificial lung surfactant replacement therapy in premature lambs
38. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: Effects of dose, dispersion technique, and gestational age
39. Alveolar hyperoxic injury in rabbits receiving exogenous surfactant
40. Mitigation of pulmonary hyperoxic injury by administration of exogenous surfactant
41. A controlled clinical comparison of four different surfactant preparations in surfactant-deficient preterm lambs
42. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets
43. Comparison of exogenous surfactants in the treatment of wood smoke inhalation
44. Modified natural and synthetically reconstituted surfactant therapies for acute lung injury caused by endotoxin in rats
45. Automated image analysis of alveolar expansion patterns in immature newborn rabbits treated with natural or artificial surfactant
46. Comparison of surface properties and physiologic effects of a synthetic and a natural surfactant in preterm rabbits
47. Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury
48. Effect of volume and dose on the pulmonary distribution of exogenous surfactant administered to normal rabbits or to rabbits with oleic acid lung injury
49. Systematic review of prophylactic vs. rescue surfactant
50. Timing of exogenous surfactant administration in a rabbit model of acute lung injury
51. Comparison of rapid bolus instillation with simplified slow administration of surfactant in lung lavaged rats
52. Prevention of neonatal respiratory distress syndrome by tracheal instillation of surfactant: A randomized clinical trial
53. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants
54. Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome
55. Surfactant replacement therapy at birth: Final analysis of a clinical trial and comparisons with similar trials
56. Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: A randomized controlled trial of prophylaxis versus treatment
57. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks gestation
58. Comparison of two strategies for surfactant prophylaxis in very premature infants: A multicenter randomized trial
59. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation
60. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome
61. A multicenter randomized masked comparison of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome
62. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome
63. Calf's lung surfactant extract in acute hypoxemic respiratory failure in children
64. Instillation of calf lung surfactant (calfactant) extract is beneficial in pediatric acute hypoxemic respiratory failure
65. Biosynthesis, secretion, and recycling of surfactant components